Centre for Addiction and Mental Health
Centre for Addiction and Mental Health
Toronto, Ontario, Canada10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Effectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Not applicable | 2026-08-20 | NCT05142683 | |
| Psilocybin for Treatment-Resistant Depression in Autism | Depressive Disorder, Treatment-Resistant, autism spectrum disorder, depressive disorder, mood disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Active, not recruiting | Phase 1 | 2026-08-06 | NCT06731621 | |
| Cannabidiol Medication Intervention Trial | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-07-31 | NCT06014424 | |
| CAMH PARTNERs Integrated Care Study | anxiety, anxiety disorder, depressive disorder, psychiatric disorder | Active, not recruiting | Not applicable | 2026-04-13 | NCT02345122 | |
| Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD) | Cognition Disorders, Cognitive Dysfunction, Disease Attributes, Disease Progression, Mild Cognitive Impairment, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cognitive disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Active, not recruiting | Not applicable | 2026-04-09 | NCT02386670 | |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | Chemically-Induced Disorders, alcohol-related disorders, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 2 | 2026-02-12 | NCT07405606 | |
| Presynaptic Imaging in Major Depressive Episodes After COVID-19 | Anhedonia, COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Neurobehavioral Manifestations, Neurologic Manifestations, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, Signs and Symptoms, depressive disorder, long COVID-19, lung disorder, major depressive disorder, mood disorder, nervous system disorder, pneumonia, psychiatric disorder, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-02-11 | NCT06086366 | |
| Nabilone for Agitation Blinded Intervention Trial | Alzheimer disease, Chemically-Induced Disorders, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, cannabis dependence, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, substance-related disorder, tauopathy | Recruiting | Phase 3 | 2026-01-28 | NCT04516057 | |
| Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial | Chemically-Induced Disorders, nicotine dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 4 | 2025-12-11 | NCT06534047 | |
| Neuromodulation for Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Not applicable | 2024-12-17 | NCT05580211 |